On the other hand, some data on chronic administration of long acting GLP1RAs have established that deceleration of gastric emptying does continue albeit less compared to short-acting GLP1RAs
3 The 14.9% figure for Wegovy 2.4 mg comes from STEP 1, the registration trial of 1,961 adults living with obesity but no type 2 diabetes, published in NEJM in 2021
However, some may still experience occasional symptoms, especially after a dose increase or if certain foods are consumed
Ingesting a meal results in an elevation of serum glucose
How will your team distinguish between medication side effects and Crohn's disease activity
If you are looking for a related overview of side effects and early adjustment, this semaglutide side effects guide can help set expectations